Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion

Oncogene

Volumn 29, Issue 49, 2010, Pages 6452-6463

  Nevo, J ^a,b   Mai, A ^a,b   Tuomi, S ^a,b   Pellinen, T ^a,b   Pentikainen O T ^c   Heikkila P ^d   Lundin, J ^d   Joensuu, H ^d   Bono, P ^d   Ivaska, J ^a,b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

adhesion; breast cancer; integrin; invasion; MDGI; migration

Indexed keywords

ALPHA INTEGRIN; COLLAGEN TYPE 1; CYTOPLASM PROTEIN; FIBRONECTIN; HETERODIMER; MAMMARY DERIVED GROWTH INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TISSUE MICROARRAY;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE I; DISEASE-FREE SURVIVAL; EXTRACELLULAR MATRIX; FATTY ACID-BINDING PROTEINS; FEMALE; FIBRONECTINS; HUMANS; INTEGRIN ALPHA CHAINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 78650018068     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.376     Document Type: Article

References (47)

1. Anthis NJ, Wegener KL, Ye F, Kim C, Goult BT, Lowe ED et al. (2009). The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J28: 3623-3632.
2. Bazzoni G, Shih DT, Buck CA, Hemler ME. (1995). Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J Biol Chem 270: 25570-25577.
3. Bouaouina M, Lad Y, Calderwood DA. (2008). The N-terminal domains of talin cooperate with the phosphotyrosine binding-like domain to activate beta1 and beta3 integrins. J Biol Chem 283: 6118-6125.
4. Bouvard D, Vignoud L, Dupe-Manet S, Abed N, Fournier HN, Vincent-Monegat C et al. (2003). Disruption of focal adhesions by integrin cytoplasmic domain-associated protein-1 alpha. J Biol Chem 278: 6567-6574.
5. Brandt DT, Baarlink C, Kitzing TM, Kremmer E, Ivaska J, Nollau P et al. (2009). SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrin. Nat Cell Biol 11: 557-568.
6. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. (2009). Anti-integrin monoclonal antibodies. J Cell Sci 122: 4009-4011.
7. Bottcher RT, Lange A, Fassler R. (2009). How ILK and kindlins cooperate to orchestrate integrin signaling. Curr Opin Cell Biol 21: 670-675.
8. Clark AJ, Neil C, Gusterson B, McWhir J, Binas B. (2000). Deletion of the gene encoding H-FABP/MDGI has no overt effects in the mammary gland. Transgenic Res 9: 439-444.
9. Czuchra A, Meyer H, Legate KR, Brakebusch C, Fassler R. (2006). Genetic analysis of beta1 integrin "activation motifs" in mice. J Cell Biol 174: 889-899.
10. Gietz RD, Woods RA. (2002). Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350: 87-96.
11. Harburger DS, Bouaouina M, Calderwood DA. (2009). Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem 284: 11485-11497.
12. Hertzel AV, Bernlohr DA. (2000). The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 11: 175-180.
13. Huttenlocher A, Sandborg RR, Horwitz AF. (1995). Adhesion in cell migration. Curr Opin Cell Biol 7: 697-706.
14. Huynh H, Alpert L, Pollak M. (1996). Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865-4870.
15. Huynh H, Pollak M. (1997). Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res 3: 2151-2156.
16. Hynes RO. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
17. Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, Andersson AC, Wahlby C et al. (2007). In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 6: 1500-1509.
18. Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. (2001). Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration. Nat Cell Biol 3: 316-320.
19. Kloeker S, Major MB, Calderwood DA, Ginsberg MH, Jones DA, Beckerle MC. (2004). The kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem 279: 6824-6833.
20. Koistinen P, Pulli T, Uitto VJ, Nissinen L, Hyypi T, Heino J. (1999). Depletion of alphaV integrins from osteosarcoma cells by intracel-lular antibody expression induces bone differentiation marker genes and suppresses gelatinase (MMP-2) synthesis. Matrix Biol 18: 239-251.
21. Kurtz A, Vogel F, Funa K, Heldin CH, Grosse R. (1990). Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. J Cell Biol 110: 1779-1789.
22. Lau TL, Kim C, Ginsberg MH, Ulmer TS. (2009). The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J 28: 1351-1361.
23. Legate KR, Wickstrom SA, Fassler R. (2009). Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 23: 397-418.
24. Lehtonen JV, Still DJ, Rantanen VV, Ekholm J, Bjorklund D, Iftikhar Z et al. (2004). BODIL: a molecular modeling environment for structure-function analysis and drug design. J Comput Aided Mol Des 18: 401-419.
25. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L et al. (2001). Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 19: 28-36.
26. Luo BH, Springer TA, Takagi J. (2004). A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol 2: e153.
27. Luque A, Gomez M, Puzon W, Takada Y, Sanchez-Madrid F, Cabanas C. (1996). Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem 271: 11067-11075.
28. Lucke C, Rademacher M, Zimmerman AW, van Moerkerk HT, Veerkamp JH, Ruterjans H. (2001). Spin-system heterogeneities indicate a selected-fit mechanism in fatty acid binding to heart-type fatty acid-binding protein (H-FABP). Biochem J 354: 259-266.
29. Mattila E, Pellinen T, Nevo J, Vuoriluoto K, Arjonen A, Ivaska J. (2005). Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. Nat Cell Biol 7: 78-85.
30. Millon-Fremillon A, Bouvard D, Grichine A, Manet-Dupe S, Block MR, Albiges-Rizo C. (2008). Cell adaptive response to extracellular matrix density is controlled by ICAP-1-dependent beta1-integrin affinity. J Cell Biol 180: 427-441.
31. Nevo J, Mattila E, Pellinen T, Yamamoto DL, Sara H, Iljin K et al. (2009). Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin Cancer Res 15: 6570-6581.
32. Pellinen T, Arjonen A, Vuoriluoto K, Kallio K, Fransen JA, Ivaska J. (2006). Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins. J Cell Biol 173: 767-780.
33. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. (1992). Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89: 9064-9068.
34. Shi X, Ma YQ, Tu Y, Chen K, Wu S, Fukuda K et al. (2007). The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem 282: 20455-20466.
35. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J et al. (2006). Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3: 995-1000.
36. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM et al. (2003). Talin binding to integrin beta tails: a final common step in integrin activation. Science 302: 103-106.
37. Takala H, Nurminen E, Nurmi SM, Aatonen M, Strandin T, Takatalo M et al. (2008). Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood 112: 1853-1862.
38. Tuomi S, Mai A, Nevo J, Laine JO, Vilkki V, hman TJ et al. (2009). PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci Signal 2: ra32.
39. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW et al. (2002). Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94: 1494-1503.
40. Wang HL, Kurtz A. (2000). Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108. Oncogene 19: 2455-2460.
41. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E et al. (2004). Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64: 8585-8594.
42. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137: 231-245.
43. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH et al. (2007). Structural basis of integrin activation by talin. Cell 128: 171-182.
44. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U et al. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159-170.
45. Vinogradova O, Vaynberg J, Kong X, Haas TA, Plow EF, Qin J. (2004). Membrane-mediated structural transitions at the cytoplas-mic face during integrin activation. Proc Natl Acad Sci USA 101: 4094-4099.
46. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D et al. (2007). Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67: 659-664.
47. Zhang X, Jiang G, Cai Y, Monkley SJ, Critchley DR, Sheetz MP. (2008). Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol 10: 1062-1068.